The effect of preoperative levosimendan on hemodynamic function and myocardial injury in patients with impaired left ventricular function undergoing CABG with cardiopulmonary bypass

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201120001

Enrollment

Registered

2020-11-20

Start date

2019-02-26

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypotension arrhythmia headache nausea and vomiting insomnia diarrhea or constipation Levosimendan CABG impaired left ventricular function cardiopulmonary bypass

Interventions

preoperative Levosimendan in patients with impaired left ventricular function undergoing CABG with cardiopulmonary bypass compared with placebo,preoperative placebo in patients with impaired left vent

Active Comparator Drug,Placebo Comparator Drug

Levosimendan,placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who schedule for CABG with CPB LVEF </= 35%

Exclusion criteria

Exclusion criteria: emergency surgery concomitant valve surgery or aortic surgery preoperative renal failure (CrCl 120 bpm) prior history of torsade de pointe

Design outcomes

Primary

Measure	Time frame
Higher hemodynamic parameter and lower cardiac enzyme marker postoperative 48 hours blood test for cardiac enzyme, intensive monitoring of hemodynamic parameter by insert PA catheter48	—

Secondary

Measure	Time frame
Length of hospital stay and ICU stay, post operative complication mortality, intubation time 3 month report outcome following standard definition	—

Countries

Thailand

Contacts

Public ContactNucharat Wattanapulsab

Faculty of Medicine, Chiang Mai university

kikzusoooo@gmail.com0809722828

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026